EUVIMEDEUVIMED entdecken
Multizentrische Studie

Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study

Robert D Little iD, Adrian Swaine, Rebecca Reynolds, David J Gibson, Mathilde Barrau, Francesca D'Errico, Rumneek Hampal, Miles P Sparrow, Xavier Roblin, Peter M Irving, Mark G Ward

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad248 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Robert D Little und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Drug Monitoring, Remission Induction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The exposure-response relationship is less established for adalimumab (ADA) compared with infliximab in inflammatory bowel disease (IBD). Evidence supporting therapeutic drug monitoring post dose-intensification of ADA is limited. We aimed to explore the association between ADA drug levels and Crohn’s disease (CD) activity at loss of response, and at 6 and 12 months post dose-intensification.

Methods

We performed a retrospective study of adult patients with CD receiving dose-intensified weekly ADA following secondary loss of response at 3 tertiary centers across 5 years. ADA trough levels were analyzed using a drug-sensitive enzyme-linked immunosorbent assay at loss of response, and 6 and 12 months after dose-intensification. Rates of clinical remission, objective remission (C-reactive protein <5 mg/L, fecal calprotectin <150 µg/g, or absence of inflammation at endoscopy or imaging), and ADA failure were investigated.

Results

A total of 131 CD patients were included, with a median disease duration of 9 (interquartile range, 4-17) years. 51% were biologic exposed prior to ADA and 50% received concomitant immunomodulators. Baseline drug levels measured at secondary loss of response did not discriminate between subsequent responders and non-responders at either 6 or 12 months post dose-intensification. However, both higher drug levels at 6 and 12 months and a higher increment from baseline were associated with improved outcomes. On receiver-operating characteristic analyses, post-escalation ADA drug levels >10.7 µg/mL (area under the receiver-operating characteristic curve [AUROC], 0.66; P = .013) and >10.9 µg/mL (AUROC, 0.67; P = .032) were associated with objective remission at 6 and 12 months, respectively.

Conclusions

Drug levels following dose-intensification rather than at the time of secondary loss of response were associated with subsequent CD remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAdalimumabDrug MonitoringRemission InductionHumansRetrospective StudiesFemaleMaleAdultMiddle AgedDose-Response Relationship, DrugYoung AdultTreatment OutcomeAnti-Inflammatory Agents

Stichwörter der Autor:innen

Crohn’s diseaseadalimumabtherapeutic drug monitoring

Substanzen

AdalimumabAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Australia.
  • Department of Gastroenterology, Redcliffe Hospital, Redcliffe, Australia.
  • Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Gastro-entérologie et Hépatologie, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France.
  • Department of Gastroenterology and Endoscopy, Miulli Hospital, Acquaviva delle Fonti, Italy.

ORCID-Profile: Robert D Little

Zitieren

APA

Little, R. D., Swaine, A., Reynolds, R., Gibson, D. J., Barrau, M., D'Errico, F., Hampal, R., Sparrow, M. P., Roblin, X., Irving, P. M., & Ward, M. G. (2024). Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad248

Vancouver

Little RD, Swaine A, Reynolds R, Gibson DJ, Barrau M, D'Errico F, et al. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad248

BibTeX
@article{Little2024,
  author = {Little, Robert D and Swaine, Adrian and Reynolds, Rebecca and Gibson, David J and Barrau, Mathilde and D'Errico, Francesca and Hampal, Rumneek and Sparrow, Miles P and Roblin, Xavier and Irving, Peter M and Ward, Mark G},
  title = {Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad248}
}
Kostenlos starten →